Eli Lilly's high-profile failure in cardiovascular disease is a boon to Regeneron, Amgen, and Esperion Therapeutics. The backstory Studies have shown that using statins to lower bad cholesterol levels ...
Eli Lilly's decision to stop phase 3 studies of its cholesteryl ester transfer protein (CETP) inhibitor evacetrapib in patients with atherosclerotic cardiovascular disease adds another expensive, late ...
Dezima Pharma (‘Dezima’) has announced the in-licensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of ...
A third of the population have genes that could help them in the fight against heart disease, say scientists. A study of 147,000 patients suggests that certain types of the CETP gene might increase ...
The mothballing of Eli Lilly'sonce-promising next-generation cholesterol drug, evacetrapib, eliminates a potential competitor toRegeneron and Amgen's recently launched cholesterol busters while also ...
Image source: Eli Lilly. Studies have shown that using statins to lower bad cholesterol levels leads to fewer life-threatening cardiac events and, as a result, statins, which lower cholesterol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results